195 related articles for article (PubMed ID: 35147864)
1. Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.
Marzęcka M; Niemczyk A; Rudnicka L
Clin Rev Allergy Immunol; 2022 Oct; 63(2):289-296. PubMed ID: 35147864
[TBL] [Abstract][Full Text] [Related]
2. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
3. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
4. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
He L
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Suga T; Oiwa H; Ishida M; Iwamoto Y
Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
[TBL] [Abstract][Full Text] [Related]
7. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.
Yang H; Peng Q; Yin L; Li S; Shi J; Zhang Y; Lu X; Shu X; Zhang S; Wang G
Arthritis Res Ther; 2017 Nov; 19(1):259. PubMed ID: 29178913
[TBL] [Abstract][Full Text] [Related]
8. Using autoantibody signatures to define cancer risk in dermatomyositis.
Turnier JL; Kahlenberg JM
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040442
[TBL] [Abstract][Full Text] [Related]
9. Dermatomyositis: Clinical features and pathogenesis.
DeWane ME; Waldman R; Lu J
J Am Acad Dermatol; 2020 Feb; 82(2):267-281. PubMed ID: 31279808
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].
Bodoki L; Budai D; Nagy-Vincze M; Griger Z; Betteridge Z; Dankó K
Orv Hetil; 2015 Sep; 156(36):1451-9. PubMed ID: 26320599
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
14. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.
Fredi M; Cavazzana I; Ceribelli A; Cavagna L; Barsotti S; Bartoloni E; Benucci M; De Stefano L; Doria A; Emmi G; Fabris M; Fornaro M; Furini F; Giudizi MG; Govoni M; Ghirardello A; Iaccarino L; Iannone F; Infantino M; Isailovic N; Lazzaroni MG; Manfredi M; Mathieu A; Marasco E; Migliorini P; Montecucco C; Palterer B; Parronchi P; Piga M; Pratesi F; Riccieri V; Selmi C; Tampoia M; Tripoli A; Zanframundo G; Radice A; Gerli R; Franceschini F;
Clin Rev Allergy Immunol; 2022 Oct; 63(2):240-250. PubMed ID: 35092577
[TBL] [Abstract][Full Text] [Related]
15. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.
Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N;
J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170
[TBL] [Abstract][Full Text] [Related]
16. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.
Gono T; Kuwana M
Expert Rev Clin Immunol; 2020 Jan; 16(1):79-89. PubMed ID: 31779485
[No Abstract] [Full Text] [Related]
17. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
18. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
19. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
20. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]